$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Medical drugs
Medical drugs
Medical drugs-Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
The therapeutic effect and real feedback of Avonib (Tosuvo) on leukemia patients
2026-02-01 22:25:32
Check Details
Can I stop taking Mitotane once I start taking it?
2026-02-01 22:25:32
Check Details
Analysis of the differences between pemetinib (Dabotan) and first-, second- and third-generation targeted drugs
2026-02-01 22:25:32
Check Details
Erdafitinib (Boke) belongs to which generation of targeted drugs and its differences from similar drugs
2026-02-01 22:25:32
Check Details
When was Erlotinib officially launched in China and its post-marketing applications?
2026-02-01 22:25:32
Check Details
Can tofacitinib (Shangjie) be taken for a long time and recommendations for safe use by patients with chronic diseases
2026-02-01 22:25:32
Check Details
Discussion on whether taking cycloserine for three months will increase the risk of leukemia
2026-02-01 22:25:32
Check Details
What kind of important antibacterial drugs does linezolid (Siwo) belong to and its hierarchical management status?
2026-02-01 22:25:32
Check Details
Patients’ personal experiences after taking Ribociclib (Kaillon) for one year, including efficacy stability and side effects
2026-02-01 22:25:32
Check Details
Analysis of which immune antibody type Cemiplimab, as a PD-1 antibody drug, belongs to
2026-02-01 22:25:32
Check Details
Recommended dosage of daprodustat and individualized dosage adjustment plans for different patient groups
2026-02-01 22:25:32
Check Details
Differences in efficacy and indications between durvalumab (durvalumab) and pembrolizumab
2026-02-01 22:25:32
Check Details
1
2
...
2431
2432
2433
2434
2435
2436
2437
2438
2439
2440
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Neurokinin Receptor Antagonists: A Non-Hormonal Approach to Menopausal Hot Flashes and Sleep Disturbances
2
FDA Approves Tauklarify for Tau PET Imaging in Alzheimer's Disease Assessment
3
First CELMoD Drug Zenbexus Wins FDA Accelerated Approval for Multiple Myeloma
4
FDA Approves First mRNA Flu Vaccine mFLUSIVA
5
FDA Approves Orzeyful, the World's First Orexin Receptor Agonist for Narcolepsy Type 1, Ushering in a New Era of Root-Cause Therapy
6
FDA Approves Lytenava: First Ophthalmic Bevacizumab for Wet AMD
7
AbbVie’s TEPKINLY (epcoritamab) Plus R² Granted EU Approval for Relapsed/Refractory Follicular Lymphoma
8
Global Oncology Update: Breakthroughs in Advanced Cancer Survival and Novel Therapies
9
Phase 1 Study Progress of Ceralasertib in Combination with Durvalumab for Advanced NSCLC and HNSCC
10
Global Breakthroughs in Cancer Drugs and Advanced Treatment Technologies
11
ROS and Cancer: The Potential of Natural Antioxidants
12
SKYSCRAPER-02C Study: New Hope for Extensive-Stage Small Cell Lung Cancer Treatment